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Clinical Presentation, Course, and Prognostic Factors
in Lymphocyte-Predominant Hodgkin’s Disease and
Lymphocyte-Rich Classical Hodgkin’s Disease:
Report From the European Task Force on Lymphoma
Project on Lymphocyte-Predominant Hodgkin’s Disease
By Volker Diehl, Michael Sextro, Jeremy Franklin, Martin-Leo Hansmann, Nancy Harris, Elaine Jaffe, Sibrand Poppema,
Martin Harris, Kaarle Franssila, Jan van Krieken, Theresa Marafioti, Ioannis Anagnostopoulos, and Harald Stein
Purpose: Recent studies have suggested that lympho-
cyte-predominant Hodgkin’s disease (LPHD) is both clini-
cally and pathologically distinct from other forms of
Hodgkin’s disease, including classical Hodgkin’s dis-
ease (CHD). However, large-scale clinical studies were
lacking. This multicenter, retrospective study investi-
gated the clinical characteristics and course of LPHD
patients and lymphocyte-rich classical Hodgkin’s dis-
ease (LRCHD) patients classified according to morpho-
logic and immunophenotypic criteria.
Materials and Methods: Clinical data and biopsy ma-
terial of all available cases initially submitted as LPHD
were collected from 17 European and American centers,
stained, and reclassified by expert pathologists.
Results: The 426 assessable cases were reclassified
as LPHD (51%), LRCHD (27%), CHD (5%), non–Hodgkin’s
lymphoma (3%), and reactive lesion (3%); 11% of cases
were not assessable. Patients with LPHD and LRCHD
were predominantly male, with early-stage disease
and few risk factors. Patients with LRCHD were signifi-
cantly older. Survival and failure-free survival rates
with adequate therapy were similar for patients with
LPHD and LRCHD, and were stage-dependent and not
significantly better than stage-comparable results for
CHD (German trial data). Twenty-seven percent of re-
lapsing LPHD patients had multiple relapses, which is
significantly more than the 5% of relapsing LRCHD
patients who had multiple relapses. Lymphocyte-pre-
dominant Hodgkin’s disease patients had significantly
superior survival after relapse compared with LRCHD or
CHD patients; however, this was partly due to the
younger average age of LPHD patients.
Conclusion: The two subgroups of LPHD and LRCHD
bore a close clinical resemblance that was distinct from
CHD; the course was similar to that of comparable
nodular sclerosis and mixed cellularity patients. Thor-
ough staging is necessary to detect advanced disease in
LPHD and LRCHD patients. The question of how to treat
such patients, either by reducing treatment intensity or
following a ‘‘watch and wait’’ approach, remains unan-
swered.
J Clin Oncol 17:776-783. r 1999 by American Society
of Clinical Oncology.
FOR MORE THAN 50 years, efforts have been made tosubclassify Hodgkin’s disease (HD) pathologically.
The underlying aims of these efforts were to establish
reproducible as well as clinically meaningful categories and
to understand better the underlying mechanisms of the
disease. The most commonly adopted scheme is the Rye
classification, which is a modification of the classification of
Lukes and Butler1,2 established in 1966. Lymphocyte-
predominant Hodgkin’s disease (LPHD) was defined as
containing rare Reed-Sternberg–like cells mixed with atypi-
cal cells (referred to as ‘‘lymphocytic and histiocytic’’ type)
in a background of great numbers of lymphocytes. In recent
studies, LPHD accounts for 3% to 8% of Hodgkin’s cases in
Western countries.2,3 In 1994, the Revised European-
American Classification of Lymphoid Neoplasms (REAL
classification) proposed the following categories of HD:
nodular lymphocyte-predominant Hodgkin’s disease, nodu-
lar sclerosis (NS), mixed cellularity (MC), lymphocyte
depletion (LD), lymphocyte-rich classical HD (LRCHD; a
provisional entity), and unclassifiable cases (UC).4 This
classification system proposed that nodular lymphocyte-
predominant Hodgkin’s disease is morphologically, biologi-
cally, and clinically distinct from other types of HD, termed
classical HD (CHD), including NS, MC, LD, and LRCHD.
Lymphocyte-predominant Hodgkin’s disease was reported
to present typically as early-stage disease, with slow progres-
sion and excellent outcome under standard therapy. A
tendency toward more secondary non–Hodgkin’s lympho-
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mas was noted, but this remained equivocal.5-7 The category
of LRCHD was introduced as a provisional category for
cases with a background consisting predominantly of lym-
phocytes, but with tumor cells of the classical Hodgkin’s/
Reed-Sternberg type (CD30- and/or CD15-positive, but
CD20-negative). In contrast, the tumor cells of LPHD
express B-cell antigens such as CD20 and rarely express
CD15 or CD30. It was postulated that LRCHD would
behave similarly to CHD of the NS or MC type. The relative
rarity of LRCHD and LPHD has so far prevented conclusive
clinical studies. The multicenter effort reported here was
designed to gain a better understanding from cases that were
reviewed by expert pathologists in a homogeneous fashion.
In particular, the study aimed to answer the following
questions regarding LPHD and LRCHD cases: (1) What is
the initial presentation? (2) What is the clinical course, with
respect to survival and failure-free survival, response, and
relapse rates? (3) Do LPHD and LRCHD differ in clinical
features? (4) Is there clinical evidence for a close relation to
non–Hodgkin’s lymphoma (NHL)? (5) What kind of clinical
management can be recommended?
MATERIALS AND METHODS
Selection of Cases
Clinical data and biopsy material (paraffin blocks) of all available
cases diagnosed initially as LPHD were collected from 17 European and
American centers (Table 1), stained, and classified by a team of expert
pathologists. Seven patients who were not treated or had surgery only
and patients younger than 16 years were excluded from the analysis.
Diagnostic Review Procedure
The methods of the pathology panel review will be described in detail
elsewhere. In brief, cases initially considered to be LPHD according to
the Rye classification were newly classified according to morphologic
and immunohistochemical criteria using the REAL classification.
Eighty cases were excluded from further analysis for the following
reasons: (1) the sample was too small, (2) immunostaining was
technically inappropriate or impossible, or (3) no corresponding clinical
data were available. The new diagnoses (REAL) of the 426 cases for
which both clinical data and paraffin blocks were available were as
follows: 51% LPHD (n 5 219 cases), 27% LRCHD (n 5 115), 3% NHL
(n 5 12), 5% CHD (n 5 19), 3% reactive lesions (n 5 14), and 11%
technically inadequate sample (n 5 47). All cases were reviewed
without prior knowledge of any corresponding clinical data.
No significant differences in patient characteristics or survival results
could be observed among the nodular, diffuse, or nodular-and-diffuse
cases of LPHD. Therefore, these subgroups were pooled for this
analysis into one single group of LPHD. Non–Hodgkin’s lymphoma
and CHD cases presented with a significantly higher stage and worse
outcome. Details will not be presented here, because (1) these sub-
groups are too small for reliable analysis, and (2) they are not
representative of CHD or NHL as a whole, because all cases had been
initially diagnosed as LPHD (Rye). Some patients with reactive lesions
nevertheless had HD in later biopsies (4 of 11 patients), which could
either mean that biopsies were not representative or preceded the
development of a true malignancy.
The following clinical variables were collected centrally in Cologne:
trial identifier (where appropriate), patient identifier, sex, age at
diagnosis, laparotomy, stage, systemic symptoms, extranodal involve-
ment, mediastinal mass, bulky disease, splenic involvement, infradia-
phragmatic involvement, sites of organ involvement, start, end, type and
result of primary therapy, relapse with date, stage and histology, vital
status, date and cause of death, and date and status of last observation.
No laboratory data were collected. Inconsistencies and incomplete data
sets were corrected with the help of the participating centers as
necessary. The therapy regimens were grouped into ‘‘MOPP-like’’
(mechlorethamine, vincristine, procarbazine, prednisone), ‘‘ABVD-
like’’ (doxorubicin, bleomycin, vinblastine, 5-[3,3-dimethyl-1-triazeno]-
imidazole-4-carboxamide), ‘‘MOPP/ABVD-like,’’ and ‘‘other’’; MOPP/
ABVD-like comprised alternating as well as hybrid regimens. Statisti-
cal analyses were performed with the SPSS Software (SPSS Inc,
Chicago, IL), Version 6.1 for Microsoft Windows. Differences in the
distribution of variables were assessed using Pearson’s x2 test. Kaplan-
Meier estimates were calculated for overall survival (SV) and failure-
free survival (FFS); comparisons of failure time data used the log-rank
test. All reported P values are two-sided. Survival and FFS are defined
as the time from diagnosis to death or the time from diagnosis to an
event, respectively. Hodgkin’s-specific events for FFS included not
achieving a complete remission (CR) after primary treatment, relapse,
and death from Hodgkin’s disease or NHL. Nonspecific events included
death from any other cause. Hodgkin’s-specific measures were used for
most analyses, because we are interested in the biology of the disease
and not in treatment-related or other deaths; however, SV after relapse
was analyzed nonspecifically. Exploratory multivariate analyses for the
evaluation of individual contributions of potential prognostic factors
(age, sex, stage, and B symptoms, together with diagnosis, morpho-
logic, and immunohistologic characteristics as recorded by the pathol-
ogy panel) were performed using Cox-regression. Survival analyses
were repeated with a stratification for center and for decade; stratifica-
tion did not significantly alter the results obtained.
Table 1. Participating Centers
Center
No. of
Assessable
Cases
Christie Hospital, Manchester, United Kingdom 90
Helsinki University Central Hospital, Helsinki, Finland 47
German Hodgkin’s Lymphoma Study Group, Cologne, Germany 40
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy 37
Swedish National Health Care Programme, Uppsala, Sweden 32
Mayo Clinic, Rochester, Minnesota, USA 30
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 29
Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom 26
St. Bartholomew’s Hospital, London, United Kingdom 24
Akademisch Ziekenhuis Leiden, Leiden, the Netherlands 24
M.D. Anderson Cancer Center, Houston, Texas, USA 12
Institut Bergonie´, Bordeaux, France 11
Karolinska Hospital, Stockholm, Sweden 11
Hospital Gregorio Maran˜o´n, Madrid, Spain 6
Universita` degli Studie ‘‘La Sapienza,’’ Rome, Italy 6
Centre Hospitalier Lyon-Sud, Lyons, France 1
TOTAL 426
CLINICAL FEATURES OF LPHD AND LRCHD 777
Downloaded from ascopubs.org by Radboud University Nijmegen on March 19, 2019 from 131.174.248.149
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
RESULTS
Patient Characteristics
Patient characteristics for LPHD and LRCHD cases are
listed in Table 2. Patients with LPHD and LRCHD had
similar presentations: most patients were male (74% v 69%),
had stage I or II disease (80% v 70%), and had few or no risk
factors. However, LRCHD patients had a higher median age
(35 v 43 years), had a mediastinal mass more often (although
still rarely) (7% v 15%), or had stage III disease (14% v
24%). No differences in the distribution of risk factors could
be observed when stage was considered (data not shown).
Approximately one half of the patients of any stage were
staged by laparotomy. Liver, bone marrow, and lung were
the most frequently involved sites of organ involvement.
Median observation time was 6.8 years for patients with
LPHD and 8.2 years for patients with LRCHD.
Therapy
Most patients were treated in the 1980s. Patients were
treated according to the protocols that were in effect at the
time of diagnosis in the participating institutions.
Table 3 lists details about the treatment modality by
disease stage. Chemotherapy was MOPP-like in 49% of
LPHD and LRCHD patients, ABVD-like in 4%, MOPP/
ABVD-like in 36%, and was other than the above categories
in 11%; these proportions were similar for patients receiving
chemotherapy alone and for those receiving combined
modality treatment. On the whole, therapy was considered to
be adequate for stage. Ninety-nine percent of stage I and
95% of stage II patients received radiotherapy or combined
modality treatment. Eighty-one percent of stage III and 95%
of stage IV patients received chemotherapy or chemotherapy
plus radiotherapy. There were no significant differences in
primary treatment between LPHD and LRCHD patients
according to stage (data not shown). If chemotherapy alone
was given, 94% of patients received MOPP-, ABVD-, or
MOPP/ABVD-like regimens.
Results of Therapy
Primary treatment results in both groups were virtually
identical, with 96% of LPHD and LRCHD patients experi-
encing a CR (Table 4). There were no significant differences
in treatment results between LPHD and LRCHD in analyses
restricted to patients who received radiotherapy alone,
chemotherapy alone, or combined modality therapy (data
not shown).
Figure 1 shows the corresponding HD-specific SV and
FFS. Although survival is slightly worse for LRCHD
patients, no significant difference was observed between
these groups (P 5 .067 for SV; P 5 .57 for FFS). Table 5
lists the 8-year Kaplan-Meier estimates for FFS and SV in
LPHD and LRCHD, respectively, by stage. There were no
statistically significant differences in SV or FFS between the
two cohorts in an analysis stratified for stage. Early-stage
patients in both groups had good-to-excellent survival, but
treatment failures were common in both groups.
Table 2. Characteristics of LPHD and LRCHD Patients
LPHD LRCHD
PNo. % No. %
n 219 115
Age, years
. 50 18 32 .0045
Median 35 43
Male sex 74 69 NS
Stage NS
I 53 46
II 28 24
III 14 24
IV 6 6
Stage I/II infradiaphragmatic 24 15 .15
B-symptoms 10 11 NS
Mediastinal mass 7 15 .041
Bulky disease* 13 11 NS
Splenic involvement 8 15 .066
Organ involvement NS
Liver 6 3 3 3
Bone marrow 2 1 1 1
Lung 2 1 4 4
Skeleton 1 1 0
Other 5 2 3 3
Abbreviation: NS, not significant.
*Definitions of bulky disease varied among contributors.
Table 3. Therapy by Stage for LPHD and LRCHD Patients Combined
Radiotherapy
(%)
Chemotherapy
(%)
Combined
Modality
Therapy
(%)
Stage I (n 5 168) 88 1 12
Stage II (n 5 88) 57 6 38
Stage III (n 5 59) 19 41 41
Stage IV (n 5 19) 5 63 32
Table 4. Therapy Results and Relapses
LPHD LRCHD
No. % No. %
Result of primary therapy
Complete remission 210 96 110 96
Partial remission 6 3 0 0
Progressive disease/no change 3 1 2 2
Therapy not complete, unclear 0 0 3 2
Relapse 45 21 20 17
More than 1 relapse 12 27* 1 5*
Death 31 14 30 26
*Percentage of relapsing patients (P 5 .044).
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Relapses
Twenty-one percent of LPHD patients compared with
17% of LRCHD patients experienced a first relapse after
achieving CR (Table 4). Multiple relapses were observed in
12 of 45 relapsing patients (27%) in the LPHD group, but in
only one of 19 relapsed patients with initial LRCHD (5%).
Patients with LRCHD had a worse prognosis after relapse
(P 5 .02; Fig 2, left panel). Further analysis revealed that
this difference could partly be explained by the older
average age of LRCHD patients (Fig 2, right panel): the
median ages (at first diagnosis) of relapsing LPHD and
LRCHD patients were 34 and 40 years respectively; 9% and
25% of patients, respectively, were older than 55 years.
Nevertheless, subgroup analysis of patients younger and
older than 45 years in both groups revealed a favorable
prognosis after relapse for younger patients with LPHD
(P 5 .020; Fig 2B).
Causes of Death
Thirty-one deaths (Table 6) were observed in the LPHD
group, eight from HD (26%) and 10 from secondary
malignancies (32%). In LRCHD patients, HD was the most
common cause of death (33%), and cardiovascular (23%)
and acute treatment-related (13%) deaths occurred more
frequently with LRCHD patients than with LPHD patients.
Because of the small total number of deaths, the effect of
treatment type on the cause-specific risk of death could not
be analyzed. Data on fatal secondary malignancies are listed
in Table 7.
In multivariate analysis, clinical prognostic factors for
survival in LPHD and LRCHD were disease stage and age,
with unfavorable prognosis associated with more advanced
disease stage and older age at diagnosis. The absence of
J-chain expression was the only other adverse prognostic
factor that was confirmed by multivariate analysis of either
SV or FFS, for all cases and for LPHD. The limited number
of patients and events in each group prevented subgroup
analyses.
DISCUSSION
In our review of 426 cases diagnosed initially as LPHD
(Rye), 51% of cases were reclassified as LPHD and 27%
were reclassified as CHD with a background of lympho-
cytes, termed LRCHD. The 219 patients with LPHD were
predominantly male with early-stage disease and few ad-
verse prognostic factors, thus confirming the observations of
several previous studies.6-14 The 115 LRCHD patients
presented similarly (male predominance, early-stage dis-
ease) but were older on average, and large mediastinal mass
Fig 1. (left) Hodgkin’s-specific failure-free survival for LPHD and LRCHD; (right) Hodgkin’s-specific overall survival for LPHD and LRCHD.
Table 5. Eight-Year HD-Specific Survival and Failure-Free Survival
Kaplan-Meier Estimates With Standard Errors
Stage
LPHD
(%)
SE
(%)
LRCHD
(%)
SE
(%)
Survival
I 99 1.2 91 5.1
II 94 2.9 86 7.6
III 94 4.4 88 6.4
IV 41 30 67 19
Freedom from treatment
failure
I 85 4.3 81 6.1
II 71 7.3 76 8.7
III 62 9.8 74 8.5
IV 24 18 57 19
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was more frequent. Patients with LRCHD did not resemble
patients with CHD in distribution of disease stage and
prognostic factors.
Both groups have a good-to-excellent prognosis. Relapses
were frequent in both groups, and patients continued to
relapse within the observation period. Although Regula9
observed frequent late relapses in patients with LPHD, other
authors7,10,11 have not uniformly confirmed this finding. The
observed high frequency of relapse is not uncommon in
early-stage CHD patients treated with radiotherapy.10,15,16 In
our cohort, multiple relapses were more common and
survival after relapse was slightly better in LPHD patients
than in LRCHD patients, which may in part reflect a more
benign character of relapse. However, LRCHD patients
were older than LPHD patients, and this may have substan-
tially influenced prognosis.17
In the LPHD and LRCHD groups, there were almost as
many deaths caused by secondary tumors as were caused by
HD (14 v 18). These tumors caused 32% of deaths in the
LPHD cohort, and only a minority of these deaths were
caused by NHL. In cured HD, long-term toxicities (such as
secondary malignancies, cardiovascular accidents, and infec-
tions) play an important role in survival. This risk is further
increased with additional salvage therapy.18 In several
reports,5,9,18 but not all,7,10,11,13 a higher probability of
developing an NHL after LPHD has been described. Four of
five patients experiencing secondary NHL reported by
Fig 2. (left) Survival after relapse (nonspecific) for LPHD and LRCHD; (right) survival after relapse (nonspecific) for LPHD and LRCHD related to age (younger or
older than 45 years).
Table 6. Causes of Death
LPHD LRCHD
No. % No. %
HD 8 3.7 10 8.7
Therapy
Primary 0 3 2.6
Salvage 1 0.5 1 0.9
Cardiovascular 4 1.8 7 6.1
Secondary tumors
Acute leukemia 5 2.3 1 0.9
NHL 2 0.9 2 1.7
Solid tumor 3 1.4 1 0.9
Other
Known 6 2.7 2 1.7
Unknown 1 0.5 1 0.9
Unknown, in CR 1 0.5 2 1.7
Total deaths 31 14 30 26
Total patients 219 100 115 100
Table 7. Data on Fatal Secondary Malignancies
Case
No. Diagnosis
Cause of
Death
Age at
Death,
Years
Primary
Therapy Relapse
1 LPHD Leukemia/MDS 77 CMT No
2 LPHD Leukemia/MDS 62 RT Yes
3 LPHD Solid tumor 67 RT No
4 LPHD Leukemia/MDS 66 RT No
5 LPHD Leukemia/MDS 34 CT Yes
6 LPHD Leukemia/MDS 75 RT No
7 LPHD Solid tumor 79 CT Yes
8 LPHD NHL 57 CT No
9 LPHD NHL 51 RT No
10 LPHD Solid tumor 83 RT No
11 LRCHD Leukemia/MDS 36 CMT No
12 LRCHD NHL 72 CT No
13 LRCHD NHL 45 RT Yes
14 LRCHD Solid tumor 82 RT No
Abbreviations: MDS, myelodysplastic syndrome; CMT, combined modality
therapy; RT, radiotherapy; CT, chemotherapy.
780 DIEHL ET AL
Downloaded from ascopubs.org by Radboud University Nijmegen on March 19, 2019 from 131.174.248.149
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
Miettinen did not receive irradiation or any kind of chemo-
therapy, which suggests that most of these NHLs were not
treatment-related. Recently, a clonal relationship between
large-cell lymphoma arising from LPHD and the initial
tumor could be established.19,20 In other series, high rates of
secondary NHL (together with the B-cell origin of the tumor
cells) have led to speculation that LPHD is not HD, but a
low-grade B-cell NHL. In our present series, only two
patients with LPHD and two patients with LRCHD died
from NHL. Additionally, four nonfatal occurrences of second-
ary NHL were documented, two directly after primary
LPHD and two after one or more relapses of LPHD; there
may have been other undocumented cases. This observed
rate of 2.9% suggests that the probability of developing
secondary NHL is increased in LPHD patients when com-
pared with CHD patients. An analysis from the International
Database on Hodgkin’s Disease estimated a secondary NHL
rate of 1.0% for all HD patients at 10 years after first
diagnosis.18
Unlike low-grade NHL (eg, follicular lymphoma), most
LPHD patients presented with early-stage disease and
remained in CR. This behavior more strongly resembles that
of classical HD than that of low-grade NHL of B-cell type.
The high rate of cure, low rate of subsequent NHL or
relapse, predominance of limited nodal disease, and rela-
tively young age associated with LPHD do not fit into the
standard pattern of, for example, follicle-center lymphomas.
Recently, Kanzler and Bra¨uninger and others21-24 convinc-
ingly demonstrated that CHD as well as LPHD are both
malignant B-cell lymphomas of germinal center origin.
Thus, B-cell NHLs might well be expected to occur after
CHD, and some such cases were seen in our series. It would
be interesting to investigate by single-cell analyses the
clonal relationships of the original CHD or LPHD and the
secondary NHL.
The fact that absence of J-chain seems to define a
subgroup of LPHD cases with a poorer prognosis was
unexpected. The test for J-chain was positive for most
LPHD cases but negative in most cases of CHD. No attempt
will be made in the present clinical report to interpret these
observations conclusively. J-chain, a polypeptide that links
immunoglobulin molecules into groups of two (IgA) or five
(IgM), has been investigated in LPHD and CHD by various
authors,25,26 but without relation to clinical characteristics.
Kelenyi,27 however, reported that J-chain had significant
prognostic power in multiple myeloma; as in the present
analysis, positive cases had better results. Briefly, the
presence of J-chain indicates the ability of the cell to
produce immunoglobulins and therefore shows that the cell
is well differentiated and retains its functionality as a B cell.
This property would logically be expected to correlate with a
lower degree of malignancy.
Several authors have reported a more benign course for
paragranuloma or lymphocyte-predominant cases, and Miet-
tinen reported an 80% 10-year survival for untreated nodular
LPHD cases.1,5,28-30 Since the publication of these reports, it
has been speculated that therapy for LPHD could be reduced
without increased hazard to the patient. In our series, all
analyzed patients received standard treatment according to
stage, thus we were unable to assess the additional benefit of
standard treatment for LPHD cases compared with a ‘‘watch-
and-wait’’ strategy. However, for the clinical management of
LPHD, it should be noted that stage III and IV disease was
diagnosed in 20% of LPHD cases and 31% of LRCHD cases
in our series. This implies that thorough staging is needed
independently of the subtype of HD, as survival and freedom
from treatment failure were substantially worse for advanced-
stage patients than for those with early-stage disease. The
prognosis for both LPHD and LRCHD in this extensively
reviewed cohort was no better than for stage-matched CHD
(NS and MC cases from the German Hodgkin’s Lymphoma
Study Group, data not shown). From our data alone, there is
no rationale for a less intensive treatment of LPHD.
However, only a minority of patients in either group died
from HD. This suggests that current treatment strategies
might not be optimal in terms of late toxicity: the cumulative
risk for a secondary tumor as well as cardiac or pulmonary
death increases with time and might reverse the benefit of
treatment in the long term. Unfortunately, there are still no
prospective trials to test whether a reduction of therapy is
safe for patients with LPHD. For any such study, multicenter
efforts will be needed: the prevalence of LPHD and LRCHD
is less than 5%, and the 334 cases in this study come from a
cohort of more than 6,000 cases of HD.
Patients with LPHD and LRCHD did not show the typical
distribution of disease stage and risk factors found in
patients with NS or MC. It remains unclear why the richness
in lymphocytes correlates with slowly progressive early-
stage disease. Lymphocyte-predominant Hodgkin’s disease
and LRCHD could not be distinguished morphologically,
but only by sophisticated histopathology with the use of
immunophenotyping. Relapses in patients with LRCHD
occurred less frequently and were more often fatal than were
relapses in patients with LPHD. Multiple relapses were
relatively more frequent after LPHD than after LRCHD.
These subtle differences were found in subgroup analyses
and should thus be interpreted with caution.
This is the first report to present the clinical characteristics
and prognosis of a large series of centrally reviewed
LRCHD cases using the definition of the REAL classifica-
tion system. Clinically, LRCHD had a closer resemblance to
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LPHD than to NS or MC. As we only assessed cases that
came from a cohort of cases that were originally diagnosed
as LPHD (Rye), the whole picture of LRCHD might be
different after review of all subtypes of HD that might harbor
cases now regarded as LRCHD. To clarify this issue,
clinicopathologic studies of lymphocyte-rich cases from the
MC and NS groups are needed. The review of project cases
emphasized that the diagnosis of lymphoma should be
confirmed by expert hematopathologists, thereby allowing
adequate treatment for CHD, LPHD, or NHL.
Almost all of our patients had received, immediately after
diagnosis, a therapy regimen that was appropriate to their
initial presentation. A watch-and-wait strategy, in which no
immediate therapy is given, has been tested for stage I
follicular lymphoma patients who are without residual
disease after surgery31: the overall and relapse-free survival
of irradiated and untreated patients were similar. The main
advantage of a watch-and-wait approach would be the
avoidance of side effects and late effects of radiotherapy or
chemotherapy. Analyses have shown that although the
HD-related death rate in patients treated for HD decreases
during the years after diagnosis, the overall death rate
remains above that of the general population, largely be-
cause of cardiac failures and secondary cancers.32 Concern-
ing secondary cancers, however, one must distinguish
between those induced by treatment (leukemia, solid tumor)
and the NHLs, which are often a transformation of the initial
LPHD.19,20,33 The latter would not be avoided by a watch-and-
wait policy and might even increase, because treatment
might suppress the development of a transformed lym-
phoma.34,35 It must also be remembered that, whereas
follicular lymphoma patients have a median age of approxi-
mately 60 years and little prospect of long-term cure, LPHD
patients are typically young, and excellent long-term sur-
vival rates are possible. To answer the question of whether
patients with LPHD, at least in stage I, would fare well
without immediate treatment, we propose a global study to
compare a watch-and-wait strategy with current standard
protocols.
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